HDAC-IN-36

• UNSPSC Description:

  HDAC-IN-36 (compound 23 g) is an orally active and potent HDAC (histone deacetylase) inhibitor, with an IC50 of 11.68 nM (HDAC6). HDAC-IN-36 promotes apoptosis, autophagy and suppresses migration. HDAC-IN-36 shows anti-tumor and anti-metastatic activity, and can be used for breast cancer research[1].

• Target Antigen:

  Apoptosis; Autophagy; HDAC

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/hdac-in-36.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC1=CC(OC)=C2C(N=C(N=C2N3CCN(CC3)C)C4=CC(C)=C(C(C)=C4)OCCCCCC(NO)=O)=C1

• Molecular Weight:

  537.65

• References & Citations:

  [1]Yao D, Li C, Jiang J, et al. Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer. Eur J Med Chem. 2020;205:112648.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2482992-54-9